Key points are not available for this paper at this time.
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and eradicate cancer cells. However, only a subset of PD-L1 positive patients benefits from α-PD-1/PD-L1 therapies. Actually, PD-L1 expression is regulated by various factors, leading to the diverse significances of PD-L1 positivity. Understanding the mechanisms of PD-L1 regulation is helpful to select patients and enhance the treatment effect. In this review, we focused on PD-L1 regulators at the levels of transcription, post-transcription, post-translation. Besides, we discussed the potential applications of these laboratory findings in the clinic.
Building similarity graph...
Analyzing shared references across papers
Loading...
Ming Yi
Southwest Medical University
Mengke Niu
Zhejiang Chinese Medical University
Linping Xu
Henan Cancer Hospital
SHILAP Revista de lepidopterología
Journal of Hematology & Oncology
Huazhong University of Science and Technology
Zhengzhou University
Tongji Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Yi et al. (Thu,) studied this question.
synapsesocial.com/papers/69dab08d4a1e15904c835b98 — DOI: https://doi.org/10.1186/s13045-020-01027-5
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: